➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Colorcon
Medtronic
Mallinckrodt
Moodys

Last Updated: May 29, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BUPROPION HYDROCHLORIDE

» See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Bupropion Hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT00405912 St. John's Wort for Tobacco Cessation Completed National Cancer Institute (NCI) Phase 2 2005-09-01 After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 23%. Currently available treatments among adults are expensive and not efficacious for all tobacco users. New pharmacologic agents need to be developed and tested to achieve the Healthy People 2010 goal of less than a 12% adult tobacco use prevalence. Bupropion, an FDA approved agent for tobacco cessation, acts by inhibiting central synaptosomal reuptake of dopamine and norepinephrine. A widely used herbal antidepressant, St. John's Wort (SJW), shares a similar mechanism of action and is effective for treating mild to moderate depression. SJW is well tolerated, available over the counter, and is significantly less expensive than the established treatments for tobacco dependence. To date, no prospective clinical trial evaluating the efficacy of SJW for the treatment of tobacco use has been published. We propose to evaluate the efficacy of SJW for increasing tobacco abstinence and decreasing nicotine withdrawal symptoms in a randomized, double-blind, placebo-controlled, three-arm, parallel group, dose-ranging clinical trial. Participants (N=120) will be randomly assigned to one of the three groups and will receive a twelve-week course of SJW 900 mg per day, 1800 mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism.
OTC NCT00405912 St. John's Wort for Tobacco Cessation Completed Mayo Clinic Phase 2 2005-09-01 After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 23%. Currently available treatments among adults are expensive and not efficacious for all tobacco users. New pharmacologic agents need to be developed and tested to achieve the Healthy People 2010 goal of less than a 12% adult tobacco use prevalence. Bupropion, an FDA approved agent for tobacco cessation, acts by inhibiting central synaptosomal reuptake of dopamine and norepinephrine. A widely used herbal antidepressant, St. John's Wort (SJW), shares a similar mechanism of action and is effective for treating mild to moderate depression. SJW is well tolerated, available over the counter, and is significantly less expensive than the established treatments for tobacco dependence. To date, no prospective clinical trial evaluating the efficacy of SJW for the treatment of tobacco use has been published. We propose to evaluate the efficacy of SJW for increasing tobacco abstinence and decreasing nicotine withdrawal symptoms in a randomized, double-blind, placebo-controlled, three-arm, parallel group, dose-ranging clinical trial. Participants (N=120) will be randomly assigned to one of the three groups and will receive a twelve-week course of SJW 900 mg per day, 1800 mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism.
OTC NCT03557294 Varenicline OTC Trial on Efficacy and Safety Recruiting Los Angeles Clinical Trials Phase 4 2018-05-07 The primary goal of the proposed research is to test whether varenicline (Chantix) is safe and effective as an over-the-counter (OTC) medication.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Bupropion Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000268 Cocaine Abuse and Attention Deficit Disorder - 3 Completed New York State Psychiatric Institute N/A 1995-05-01 The purpose of this study is to evaluate cocaine abuse and Attention Deficit Disorder
NCT00000268 Cocaine Abuse and Attention Deficit Disorder - 3 Completed National Institute on Drug Abuse (NIDA) N/A 1995-05-01 The purpose of this study is to evaluate cocaine abuse and Attention Deficit Disorder
NCT00000276 Dopamine Reuptake Inhibitors of Cocaine Abuse - 1 Terminated National Institute on Drug Abuse (NIDA) Phase 1 1994-09-01 The purpose of this study is to evaluate dopamine reuptake inhibitors for cocaine abuse.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Bupropion Hydrochloride

Condition Name

Condition Name for Bupropion Hydrochloride
Intervention Trials
Smoking Cessation 39
Nicotine Dependence 33
Tobacco Use Disorder 29
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Bupropion Hydrochloride
Intervention Trials
Depression 73
Tobacco Use Disorder 70
Depressive Disorder 68
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Bupropion Hydrochloride

Trials by Country

Trials by Country for Bupropion Hydrochloride
Location Trials
United States 774
Canada 39
China 17
South Africa 8
Germany 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Bupropion Hydrochloride
Location Trials
California 49
New York 48
North Carolina 39
Texas 39
Massachusetts 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Bupropion Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Bupropion Hydrochloride
Clinical Trial Phase Trials
Phase 4 86
Phase 3 46
Phase 2/Phase 3 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Bupropion Hydrochloride
Clinical Trial Phase Trials
Completed 187
Recruiting 50
Not yet recruiting 25
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Bupropion Hydrochloride

Sponsor Name

Sponsor Name for Bupropion Hydrochloride
Sponsor Trials
National Institute on Drug Abuse (NIDA) 63
GlaxoSmithKline 29
Yale University 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Bupropion Hydrochloride
Sponsor Trials
Other 315
NIH 119
Industry 97
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Harvard Business School
Medtronic
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.